Skip to main content

Table 2 Overall and progression-free survival of patients in the two treatment groups

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Group

OS (months)

P

PFS (months)

P

Median

95% CI

Median

95% CI

Sorafenib

18

11.797–24.203

0.223

6

3.270–8.730

0.004

TACE + sorafenib

22

14.095–29.905

8

3.400–12.600

  1. CI confidence interval, OS overall survival, PFS progression-free survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us